Singapore, Mar 22, 2010: With stem cell therapy projected as the future of medicine, CordLife, Asia Pacific's largest network of stem cell banks, forays into India, with an aim to bring the facilities of stem cell therapy to the people of India in general and Mumbai in particular. CordLife received the Best Stall Award in terms of the design of the stall, company's initiative in imparting knowledge on the concept of new technology and educating the expecting mothers in the MBC Expo 2010.

Headquartered in Singapore and listed on the Australia Securities Exchange, CordLife has plans to aware and educate all would-be mothers on the benefits of Stem Cell therapy. The company is now in the initial stages of contacting various Gynecologists and tie-up with the major hospitals in Mumbai.

Cordlife played a significant role to treat cerebral palsy for the first time in Asia in December last year. In this breakthrough medical procedure, the patient, two-year-old Georgia Conn, was infused with her own cord blood stem cells in the hope to repair damaged brain tissue as a result of injury at birth, which currently has no cure. These stem cells were stored with CordLife by her parents in the eventuality that they might be needed in future.

According to Dr. Prosanto Chowdhury, Medical Officer, CordLife Sciences India Pvt. Ltd, "Clients without history of illness far outweighs number of clients with any history of illness which proves that the concept is steadily gaining momentum and people showing confidence over this".

According to Mr. Simon Hoo, General Manager, CordLife, "there has been a constant upward trend in the no. of units being stored each year and most importantly, released for therapeutic applications every year. According to our latest financial results released, the group has achieved a year on year growth of 60% in total revenue".

The company gets clients mostly through its awareness campaigns with various Hospitals and other Consumer activities. Many new clients are referred to through the existing group of clients also.

Since its official launch in January 2009 in India, CordLife has accelerated to the next level of achievement and now offers umbilical cord banking in addition to its cord blood banking service. Unlike conventional technology, that can only isolate mesenchymal stem cells, CordLife has a proven and patented technology that can isolate both mesenchymal and epithelial stem cells, the first and only in India. Mesenchymal stem cells can be used in conjunction with cord blood or bone marrow stem cells to increase the success rate of a transplant. They have also shown immense potential to treat diseases and repair injured tissues or organs. On the other hand, epithelial stem cells have the potential to grow skin and mucus membrane to treat non-healing wounds of diabetic, Hemophilia-A and traffic accident patients.

"With approximately 40.9 million people in India diagnosed with diabetes, CordLife's proven and patented umbilical cord banking technology will help to harvest stem cells that may induce faster wound healings to prevent unnecessary amputations," said Dr. Prosanto Chowdhury.